Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ILXO > ILEX Oncology > CURE for CANCER in 1999 -- Ignore unavailable to you. Want to Upgrade?

To: Jim K. who wrote (1)	1/1/1999 7:03:00 PM
From: chalu2	Read Replies (1) \| Respond to of 23

If this is in Phase I trials, it is many, many years away from the market in the U.S. There are many promising therapies; IMCL is very far along with its angiogenesis approach, for example. There's no predicting which will work--let's hope they all do! Happy New Year!

To: Jim K. who wrote (1)	6/28/1999 7:27:00 AM
From: StockMiser	Read Replies (1) \| Respond to of 23

I was wondering why no mention of the (2) products already in Phase III? Campath and DFMO. DFMO for bladder cancer was started in P3 this year (http://www.ilexoncology.com/news/pr/index.phtml?pr_id=46), with the first data set ready for review in early 2000. If things look very good, they could file for fast track and potentially be on the market late 2000. Campath (in conjunction with LKST) for Leukemia has been in P3 since 1998, and may recieve final FDA marketing approval this year. (http://www.ilexoncology.com/news/pr/index.phtml?pr_id=53). This interesting product has already recieved orpahn status as well as FDA fast track status. It's these two products that have sparked my interest in ILXO. (I generally only look at biotechs in phase 3 development.) SM